Notice Number: NOT-HG-16-009

Key Dates
Release Date: February 25, 2016

Issued by
National Human Genome Research Institute (NHGRI)

Purpose

The purpose of this Notice is to clarify the types of applications which can be submitted to PAR-16-017 "Novel Genomic Technology Development - Direct to Phase II SBIR Grant (R44)". The NIH Direct-to-Phase II program will accept
Phase II submissions regardless of the funding source for the Phase I-like proof of principle work on which the proposed Phase II research is based.

NIH strongly encourages small businesses to contact the appropriate Institute or Center early in
their application planning process to ensure their technology is of priority to the Institute/Center
Information regarding the funding opportunity submission information is changed as follows: 

Part 2. Section I. Funding Opportunity Description

The following text is deleted: 

The goal of this FOA is to enable a small business that has accomplished the objectives of a Phase I
SBIR grant through non-SBIR funds to initiate the Phase II SBIR stage of development, without
needing to perform more early stage, Phase-I-SBIR-type research. This FOA will also not accept
‘regular’ Phase II submissions from SBCs that have received a Phase I SBIR or STTR award from NIH
or any other agency that participates in the SBIR/STTR programs for projects for which applicants
now seek follow-on research and development funding. 

The following text is added: 

The NIH Direct-to-Phase II program will accept Phase II submissions regardless of the funding source
for the Phase I-like proof of principle work on which the proposed Phase II research is based, with the
following exception: Small business concerns (SBCs) eligible to submit Phase II applications for
projects that were supported with a Phase I SBIR or STTR award from NIH or any other agency are
expected to submit the regular Phase II application through SBIR/STTR solicitations as "Renewal" applications based on the awarded Phase I SBIR or STTR project. Only one Phase II application may be awarded for a specific project supported by a Phase I award. NIH policies regarding overlapping applications still apply (NOT-OD-14-082). A Phase II awardee may receive one additional, sequential Phase II award (called the NIH Phase IIB) to continue the work of an initial Phase II award.  

All other aspects of these FOAs remain unchanged.

Inquiries

Please direct all inquiries to:

Michael W. Smith, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-402-1114
Email: [email protected]